An FDA-approved rheumatoid arthritis drug targeting the IL-6 receptor significantly reduces excessive alcohol consumption in alcohol-dependent female mice. The treatment functions by blocking neuroinflammatory pathways that suppress the GABAergic braking system in the central amygdala, a mechanism corroborated by elevated IL-6 expression found in postmortem human AUD brain tissue.
